{"id":46306,"date":"2022-07-19T12:02:15","date_gmt":"2022-07-19T10:02:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/"},"modified":"2022-07-19T12:02:15","modified_gmt":"2022-07-19T10:02:15","slug":"biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/","title":{"rendered":"Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022"},"content":{"rendered":"
\n

BOULDER, Colo.–(BUSINESS WIRE)–$BDSX<\/a> #patientsfirst<\/a>—Biodesix, Inc.<\/a> (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4. Biodesix\u2019s management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. Eastern Time on the same day. Dial-in and call details are as follows:\n<\/p>\n

<\/a><\/p>\n

\nThursday, August 4th<\/sup> at 8:00 a.m. Eastern Time
\n
Domestic: 800-715-9871
\n
International: 646-307-1963
\n
Conference ID: 8620846
\n
Webcast: https:\/\/edge.media-server.com\/mmc\/p\/rf64jw58<\/a>\n<\/p>\n

\nAbout Biodesix<\/b>\n<\/p>\n

\nBiodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer eight non-invasive tests for patients with lung diseases. The blood based Nodify Lung\u00ae nodule risk assessment testing strategy, consisting of the Nodify XL2\u00ae and the Nodify CDT\u00ae tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung\u2122 strategy for lung cancer patients integrates the GeneStrat\u00ae ddPCR\u2122 test, the GeneStrat NGS\u2122 test and the VeriStrat\u00ae test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex\u00ae AI (Artificial Intelligence) platform, to collaborate with many of the world\u2019s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. Biodesix launched the SARS-CoV-2 ddPCR\u2122 test, the Platelia SARS-CoV-2 Total Ab, and the cPass\u2122 SARS-CoV-2 Neutralization Antibody test (cPass\u2122 Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. For more information about Biodesix, visit biodesix.com.\n<\/p>\n

\nNote Regarding Forward-Looking Statements<\/b>\n<\/p>\n

\nThis press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cexpect,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201copportunity,\u201d \u201cgoals,\u201d or \u201cshould,\u201d and similar expressions are intended to identify forward-looking statements. Such statements are based on management\u2019s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company’s ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix\u2019s most recent annual report on Form 10-K, filed March 14, 2022 or subsequent quarterly reports on Form 10-Q during 2022, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Bobbi Coffin
\n
bobbi.coffin@biodesix.com<\/a>
(303) 892-3203\n<\/p>\n

\nInvestors:<\/b>
Chris Brinzey
\n
chris.brinzey@westwicke.com<\/a>
(339) 970-2843\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOULDER, Colo.–(BUSINESS WIRE)–$BDSX #patientsfirst—Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4. Biodesix\u2019s management will host a conference call and webcast to discuss … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46306","6":"format-standard","7":"category-industry"},"yoast_head":"\nBiodesix to Report Second Quarter 2022 Financial Results on August 4, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOULDER, Colo.–(BUSINESS WIRE)–$BDSX #patientsfirst—Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4. Biodesix\u2019s management will host a conference call and webcast to discuss ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-19T10:02:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220719005345\/en\/1086870\/21\/Biodesix_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022\",\"datePublished\":\"2022-07-19T10:02:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\\\/\"},\"wordCount\":666,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005345\\\/en\\\/1086870\\\/21\\\/Biodesix_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\\\/\",\"name\":\"Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005345\\\/en\\\/1086870\\\/21\\\/Biodesix_Logo.jpg\",\"datePublished\":\"2022-07-19T10:02:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005345\\\/en\\\/1086870\\\/21\\\/Biodesix_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005345\\\/en\\\/1086870\\\/21\\\/Biodesix_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/","og_locale":"en_US","og_type":"article","og_title":"Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022 - Pharma Trend","og_description":"BOULDER, Colo.–(BUSINESS WIRE)–$BDSX #patientsfirst—Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4. Biodesix\u2019s management will host a conference call and webcast to discuss ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-19T10:02:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220719005345\/en\/1086870\/21\/Biodesix_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022","datePublished":"2022-07-19T10:02:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/"},"wordCount":666,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220719005345\/en\/1086870\/21\/Biodesix_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/","url":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/","name":"Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220719005345\/en\/1086870\/21\/Biodesix_Logo.jpg","datePublished":"2022-07-19T10:02:15+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220719005345\/en\/1086870\/21\/Biodesix_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220719005345\/en\/1086870\/21\/Biodesix_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/biodesix-to-report-second-quarter-2022-financial-results-on-august-4-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46306"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46306\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}